{"filings":[{"id":99401,"accession_number":"0001171843-26-003052","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst Q1 ORLADEYO rev $148.3M (+11% YoY); non-GAAP op profit $54.2M; licenses EU navenibart rights for $70M upfront","event_type":"earnings","confidence":"high","bullets":["ORLADEYO net revenue $148.3M, +11% reported, +21% ex-Europe; GAAP operating loss $701.6M includes $697.8M non-cash IPR&D charge from Astria acquisition.","Non-GAAP operating profit of $54.2M; guidance reaffirmed: FY2026 ORLADEYO rev $625-645M, total rev $635-660M, op ex $450-470M.","Licensed European navenibart rights to Neopharmed Gentili for $70M upfront, up to $275M milestones, plus 18-30% royalties.","Navenibart pivotal study ALPHA-ORBIT enrollment on track to complete by June 2026; US regulatory filing targeted by end 2027.","Appointed Sandeep Menon as Chief R&D Officer in April; ended avoralstat DME program to focus on rare diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":156413000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99400,"accession_number":"0001171843-26-002960","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioCryst licenses navenibart to Neopharmed Gentili in Europe for $70M upfront plus milestones","event_type":"other_material","confidence":"high","bullets":["BioCryst receives $70M upfront and up to $275M in regulatory/sales milestones from Neopharmed Gentili affiliate.","Tiered royalties on net sales of navenibart in Europe range from 18% to 30%.","Navenibart Phase 3 in hereditary angioedema on track for US regulatory filing by end of 2027.","Agreement builds on prior 2025 deal for sale of European ORLADEYO business to Neopharmed Gentili."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115380,"accession_number":"0001171843-26-001119","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst reports record FY2025 operating profit; ORLADEYO rev $601.8M (+38%); maintains FY2026 guidance","event_type":"earnings","confidence":"high","bullets":["Full year 2025 GAAP operating profit $341.0M vs loss of $2.5M in 2024; total revenues $874.8M (incl $243.3M European sale) vs $450.7M.","Non-GAAP total revenues $592.9M (+45% YoY); non-GAAP operating profit $214.2M (+198%).","ORLADEYO net revenue $601.8M (+38% YoY; +43% ex-EU); FY2026 revenue guidance maintained at $625-645M.","Completed acquisition of Astria Therapeutics (navenibart); FDA approved ORLADEYO oral pellets for pediatric HAE.","Cash $337.5M at year-end; net cash generation $85.2M ex-debt payoff and EU sale proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":874837000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115379,"accession_number":"0001140361-26-002200","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["1.01","2.01","2.03","7.01","9.01"],"status":"ready","headline":"BioCryst closes $700M Astria acquisition, adds Phase 3 HAE asset navenibart","event_type":"m_and_a","confidence":"high","bullets":["Acquired Astria for ~$700M net of cash; financed with $396.6M Blackstone loan and 37.3M shares.","Adds navenibart (Phase 3 plasma kallikrein inhibitor) offering every-3/6-month HAE dosing.","Astria CEO Jill Milne joins BioCryst board; John Ruesch becomes Chief Technical Operations Officer.","BioCryst obtained $400M term loan from Blackstone funds (5-yr, SOFR+4.5% with PIK option).","Astria's nine-month 2025 net loss $98.4M; had $227.7M cash/investments at Sep 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115376,"accession_number":"0001171843-26-000405","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K/A","filed_at":"2026-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioCryst appoints Dr. Jill Milne to Compensation and Science Committees following Astria merger close","event_type":"leadership","confidence":"high","bullets":["Merger with Astria Therapeutics completed on January 23, 2026; Astria becomes wholly owned subsidiary.","Dr. Jill C. Milne appointed to BioCryst Board of Directors effective as of closing date.","On January 20, 2026, Board appointed Dr. Milne to Compensation and Science Committees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115378,"accession_number":"0001171843-26-000213","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"BioCryst beats FY2025 ORLADEYO rev guidance; FY2026 outlook $625-645M; Astria acquisition on track","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited FY2025 ORLADEYO net revenue $601M (+37% YoY), exceeding $590-600M guidance range.","Q4 2025 ORLADEYO net revenue $151M (+22% YoY; +36% comparable basis excl European revenue).","Cash, cash equivalents, restricted cash & investments at Dec 31, 2025: $338M.","FY2026 guidance: ORLADEYO rev $625-645M; total rev $635-660M; non-GAAP op ex $380-390M (excl Astria).","Expected close of Astria Therapeutics acquisition in Q1 2026; adds $70-80M non-GAAP op ex for navenibart Phase 3 and manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":874837000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115377,"accession_number":"0001171843-26-000154","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"BioCryst increases ORLADEYO WAC by ~9% to $48,488 per 28-day pack","event_type":"other","confidence":"high","bullets":["Effective January 9, 2026, WAC for ORLADEYO (berotralstat) raised from $44,484.33 to $48,487.92 per 28-day pack.","The price increase applies to both the 150mg and 110mg capsule strengths.","BioCryst's sole marketed product ORLADEYO is approved for hereditary angioedema prophylaxis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131787,"accession_number":"0001171843-25-007909","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioCryst gets FDA approval for ORLADEYO oral pellets for HAE patients aged 2 to <12 years","event_type":"regulatory","confidence":"high","bullets":["FDA approved ORLADEYO oral pellet formulation for prophylactic therapy in HAE children aged 2 to <12 years.","First and only oral prophylactic treatment for this age group; previously only injectable options were available.","Approval supported by APeX-P trial interim data showing early and sustained attack rate reductions with no new safety signals.","BioCryst plans EU, Japan, and other regulatory filings; ORLADEYO capsule already approved for ages 12+ since Dec 2020.","More than 3,500 patients in the US have been prescribed ORLADEYO to date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131786,"accession_number":"0001171843-25-007878","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioCryst board chair Nancy Hutson to retire; Vincent Milano named successor","event_type":"leadership","confidence":"high","bullets":["Nancy J. Hutson notified retirement from BioCryst board, effective earlier of Astria acquisition close or 2026 annual meeting.","Hutson to continue as Chair and committee member until Retirement Date; cited no disagreement with board or management.","Vincent J. Milano elected as next Board Chair, effective on Hutson's Retirement Date.","Hutson served 14 years on the BioCryst board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131785,"accession_number":"0001140361-25-044110","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioCryst clears HSR hurdle for Astria acquisition; expects close Q1 2026","event_type":"m_and_a","confidence":"high","bullets":["HSR waiting period terminated early on December 3, 2025, satisfying one closing condition.","BioCryst expects the merger with Astria Therapeutics to close in Q1 2026.","Remaining conditions still required; deal previously announced.","Removal of antitrust risk is a positive step toward closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131784,"accession_number":"0001171843-25-006881","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst Q3 ORLADEYO rev $159.1M (+37%); raises FY guidance; agrees to acquire Astria","event_type":"earnings","confidence":"high","bullets":["ORLADEYO net rev Q3 $159.1M (+37% yoy); total rev $159.4M (+36%); non-GAAP op profit $51.7M (+107%).","Net income $12.9M ($0.06) vs net loss $14.0M ($0.07 loss) prior year; non-GAAP net income $35.6M ($0.17).","FY 2025 ORLADEYO rev guidance raised to $590-600M; non-GAAP op expense lowered to $430-440M; on track for positive cash flow.","Sale of European ORLADEYO business closed; proceeds used to retire remaining $198.7M Pharmakon term debt; pro forma cash $294M.","Definitive agreement to acquire Astria Therapeutics (navenibart Phase 3 HAE); expected close Q1 2026; Ron Dullinger named CCO effective Jan 1, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":468282000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131783,"accession_number":"0001140361-25-038031","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","2.02","5.02","8.01","9.01"],"status":"ready","headline":"BioCryst to acquire Astria Therapeutics for 0.59 shares + $8.55 cash per share; Q3 ORLADEYO strong","event_type":"m_and_a","confidence":"high","bullets":["Merger: each Astria share → 0.59 BCRX shares + $8.55 cash; expected close Q1 2026.","Blackstone provides $550M senior secured credit facility ($350M term loan + $50M committed delayed draw + $150M uncommitted) to fund deal.","Q3 2025: ORLADEYO demand strong with no impact from new competition (no specific figures given).","Astria CEO Jill Milne appointed to BioCryst board effective at merger close; receives $500K equity grant.","BioCryst paid off and terminated April 2023 loan agreement with BioPharma Credit PLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131782,"accession_number":"0001140361-25-036875","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"BioCryst completes sale of European ORLADEYO business; receives $250M upfront","event_type":"m_and_a","confidence":"high","bullets":["Received $250M cash from sale of European ORLADEYO assets to Neopharmed Gentili; up to $14M in milestones.","Transaction valued at ~5.4x trailing 12-month European ORLADEYO sales (through June 2025).","Will use proceeds to retire $199M Pharmakon term loan, strengthening balance sheet.","Reaffirms FY2025 revenue guidance of $580M–$600M, expects upper half excluding European revenue.","European business was approximately breakeven; divestiture improves operating margin and focuses on U.S. core."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148383,"accession_number":"0001171843-25-005265","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioCryst's Chief R&D Officer resigns after CEO selection process; to depart Sep 1, 2025","event_type":"leadership","confidence":"high","bullets":["Dr. Helen Thackray resigns as Chief R&D Officer effective Sep 1, 2025, after not being selected as next CEO.","Separation benefits include 1 year base salary, 2025 bonus (actual and target), 12 months health coverage, outplacement, accelerated equity vesting.","Consulting agreement for transition through Dec 31, 2025: monthly fee $12,500, continued equity vesting during period.","No disagreement cited with Board or management regarding company operations or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148382,"accession_number":"0001171843-25-004977","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioCryst Q2 ORLADEYO rev $156.8M (+45% YoY); net income $5.1M vs loss $12.7M","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $163.4M (+50% YoY); ORLADEYO net rev $156.8M (+45% YoY).","Operating income $29.8M (up from $8.8M); non-GAAP op income $57.0M (up from $21.9M).","Net income $5.1M ($0.02 EPS) vs net loss $12.7M ($0.06 loss) in Q2 2024.","Made additional $50M term debt paydown in July; plans to retire remaining $199M with proceeds from European ORLADEYO sale expected to close early Oct.","Full-year 2025 ORLADEYO revenue guidance maintained at $580M-$600M; pipeline on track for data in two programs by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":308887000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148381,"accession_number":"0001171843-25-004869","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BioCryst CEO Jon Stonehouse to retire Dec 31; Charlie Gayer named successor","event_type":"leadership","confidence":"high","bullets":["Jon Stonehouse retiring as CEO on Dec 31, 2025; will remain on BioCryst board.","Charlie Gayer appointed President (Aug 1, 2025) and CEO (Jan 1, 2026); previously CCO.","Gayer's base salary rises to $675k as President; expected $775k as CEO with 85% AIP target.","Gayer elected to board effective Jan 1, 2026; board size increased from nine to ten.","Stonehouse cited no disagreement; transition follows succession planning process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148380,"accession_number":"0001171843-25-004324","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BioCryst appoints Babar Ghias as CFO and Head of Corporate Development","event_type":"leadership","confidence":"high","bullets":["Babar Ghias named CFO, effective July 7, 2025; also serves as Principal Accounting Officer.","Annual base salary of $560,000; target bonus 70% of salary; one-time cash bonus of $160,000.","Inducement grants: 147,000 RSUs and options to purchase 305,000 shares, vesting over 4 years.","Ghias joins from AvenCell Therapeutics; previously EVP at Paragon Biosciences and CFO at Marathon Pharmaceuticals.","CEO Stonehouse cites Ghias' deal-making and operational experience for growth and capital deployment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167167,"accession_number":"0001140361-25-024089","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"BioCryst agrees to sell European ORLADEYO business to Neopharmed Gentili for $250M","event_type":"m_and_a","confidence":"high","bullets":["Upfront cash consideration of $250M plus up to $14M in revenue milestones if achieved before Dec 31, 2032.","Transaction expected to close in October 2025, subject to antitrust clearance and customary closing conditions.","BioCryst will continue as exclusive supplier of ORLADEYO under a supply agreement and enter IP license, brand support, and transition services agreements.","Sale includes all equity of BioCryst Ireland Limited, which holds European ORLADEYO assets and rights.","The amended IP license may extend to the pediatric line extension of ORLADEYO subject to regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167166,"accession_number":"0001171843-25-004186","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioCryst sells European ORLADEYO rights to Neopharmed Gentili for up to $264M","event_type":"m_and_a","confidence":"high","bullets":["Neopharmed Gentili pays $250M upfront, up to $14M milestones; closing expected by early October 2025.","Proceeds to retire all $249M remaining term debt, eliminating ~$70M future interest payments.","BioCryst now expects ~$700M cash and no term debt by end 2027, a $400M increase from prior guidance.","Sale includes European team; BioCryst saves at least $50M in annual operating expenses.","European ORLADEYO revenues still count toward global royalty tiers for OMERS and >$550M cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167165,"accession_number":"0001171843-25-004091","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA extends PDUFA goal date for BioCryst's ORLADEYO pediatric NDA to Dec 12, 2025","event_type":"regulatory","confidence":"high","bullets":["FDA determined submission of additional final reports and formulation data is a major amendment, extending review by three months.","New PDUFA target action date set for December 12, 2025, after original goal date extended.","NDA seeks approval of once-daily ORLADEYO oral granules for HAE in pediatric patients aged 2 to 11 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167164,"accession_number":"0001171843-25-003910","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"BioCryst shareholders approve 11M share increase in stock incentive plan at annual meeting","event_type":"other_material","confidence":"high","bullets":["Director George Abercrombie retired effective June 12, 2025 after 13 years; no disagreement cited.","Shareholders approved amended Stock Incentive Plan, increasing shares available by 11,000,000 to 81,090,000 total.","Advisory say-on-pay passed with 143.1M for vs 6.4M against; auditor Ernst & Young ratified with 174.7M for.","Director nominees Steven Galson and Alan Levin re-elected with ~146M votes each."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167163,"accession_number":"0001171843-25-003662","cik":882796,"company_name":"BIOCRYST PHARMACEUTICALS INC","ticker":"BCRX","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioCryst extends former CFO Anthony Doyle's consulting agreement through Dec 31, 2025","event_type":"leadership","confidence":"high","bullets":["Consulting Agreement extended from original end date to December 31, 2025; after that, month-to-month with 30-day notice.","Mr. Doyle provides transition services related to CFO succession at $450/hour; all other terms unchanged.","Original agreement effective April 9, 2025; extension announced on May 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}